1
|
McNair HA, Milosevic MF, Parikh PJ, van der Heide UA. Future of Multidisciplinary Team in the Context of Adaptive Therapy. Semin Radiat Oncol 2024; 34:418-425. [PMID: 39271276 DOI: 10.1016/j.semradonc.2024.08.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/15/2024]
Abstract
The implementation and early adoption of online adaptive radiotherapy (oART) has required the presence of clinicians, physicists and radiation therapists (RTT) at the treatment console. The impact on each of them is unique to their profession and must be considered for safe and efficient implementation. In the short term future, widespread adoption will depend on the development of innovative workflows, and rethinking of traditional roles and responsibilities may be required. For the future, technologies such as artificial intelligence promise to change the workflow significantly in terms of speed, automation and decision-making. However, overall communication within the team will persist in being one of the most important aspects.
Collapse
Affiliation(s)
- H A McNair
- The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK..
| | - M F Milosevic
- Radiation Medicine Program, Princess Margaret Cancer Centre and Department of Radiation Oncology, University of Toronto, Toronto, Canada
| | | | - U A van der Heide
- The Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam and department of Radiation Oncology, Leiden University Medical Centre the Netherlands, Leiden, The Netherlands
| |
Collapse
|
2
|
Kazemimoghadam M, Yang Z, Chen M, Rahimi A, Kim N, Alluri P, Nwachukwu C, Lu W, Gu X. A deep learning approach for automatic delineation of clinical target volume in stereotactic partial breast irradiation (S-PBI). Phys Med Biol 2023; 68:10.1088/1361-6560/accf5e. [PMID: 37084739 PMCID: PMC10325028 DOI: 10.1088/1361-6560/accf5e] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 04/21/2023] [Indexed: 04/23/2023]
Abstract
Accurate and efficient delineation of the clinical target volume (CTV) is of utmost significance in post-operative breast cancer radiotherapy. However, CTV delineation is challenging as the exact extent of microscopic disease encompassed by CTV is not visualizable in radiological images and remains uncertain. We proposed to mimic physicians' contouring practice for CTV segmentation in stereotactic partial breast irradiation (S-PBI) where CTV is derived from tumor bed volume (TBV) via a margin expansion followed by correcting the extensions for anatomical barriers of tumor invasion (e.g. skin, chest wall). We proposed a deep-learning model, where CT images and the corresponding TBV masks formed a multi-channel input for a 3D U-Net based architecture. The design guided the model to encode the location-related image features and directed the network to focus on TBV to initiate CTV segmentation. Gradient weighted class activation map (Grad-CAM) visualizations of the model predictions revealed that the extension rules and geometric/anatomical boundaries were learnt during model training to assist the network to limit the expansion to a certain distance from the chest wall and the skin. We retrospectively collected 175 prone CT images from 35 post-operative breast cancer patients who received 5-fraction partial breast irradiation regimen on GammaPod. The 35 patients were randomly split into training (25), validation (5) and test (5) sets. Our model achieved mean (standard deviation) of 0.94 (±0.02), 2.46 (±0.5) mm, and 0.53 (±0.14) mm for Dice similarity coefficient, 95th percentile Hausdorff distance, and average symmetric surface distance respectively on the test set. The results are promising for improving the efficiency and accuracy of CTV delineation during on-line treatment planning procedure.
Collapse
Affiliation(s)
- Mahdieh Kazemimoghadam
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Zi Yang
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Mingli Chen
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Asal Rahimi
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Nathan Kim
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Prasanna Alluri
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Chika Nwachukwu
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Weiguo Lu
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
| | - Xuejun Gu
- Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas TX, 75390 USA
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305
| |
Collapse
|
3
|
Buelens P, Ir SW, I LV, Crijns W, Ir FM, Weltens CG. Clinical Evaluation of a Deep Learning Model for Segmentation of Target Volumes in Breast Cancer Radiotherapy. Radiother Oncol 2022; 171:84-90. [PMID: 35447286 DOI: 10.1016/j.radonc.2022.04.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 04/08/2022] [Accepted: 04/11/2022] [Indexed: 12/24/2022]
Abstract
PURPOSE/OBJECTIVE(S) Precise segmentation of clinical target volumes (CTV) in breast cancer is indispensable for state-of-the art radiotherapy. Despite international guidelines, significant intra- and interobserver variability exists, negatively impacting treatment outcomes. The aim of this study is to evaluate the performance and efficiency of segmentation of CTVs in planning CT images of breast cancer patients using a 3D convolutional neural network (CNN) compared to the manual process. MATERIALS/METHODS An expert radiation oncologist (RO) segmented all CTVs separately according to international guidelines in 150 breast cancer patients. This data was used to create, train and validate a 3D CNN. The network's performance was additionally evaluated in a test set of 20 patients. Primary endpoints are quantitative and qualitative analysis of the segmentation data generated by the CNN for each level specifically as well as for the total PTV to be irradiated. The secondary endpoint is the evaluation of time efficiency. RESULTS In the test set, segmentation performance was best for the contralateral breast and the breast CTV and worst for Rotter's space and the internal mammary nodal (IMN) level. Analysis of impact on PTV resulted in non-significant over-segmentation of the primary PTV and significant under-segmentation of the nodal PTV, resulting in slight variations of overlap with OARs. Guideline consistency improved from 77.14% to 90.71% in favor of CNN segmentation while saving on average 24 minutes per patient with a median time of 35 minutes for pure manual segmentation. CONCLUSION 3D CNN based delineation for breast cancer radiotherapy is feasible and performant, as scored by quantitative and qualitative metrics.
Collapse
Affiliation(s)
- P Buelens
- KU Leuven - University of Leuven, Department of Oncology, Experimental Radiation Oncology, B-3000 Leuven, Belgium; University Hospitals Leuven, Department of Radiation Oncology, B-3000 Leuven, Belgium
| | - S Willems Ir
- Medical Imaging Research Center, University Hospitals Leuven, Leuven, Belgium; Department of Electrical Engineering, ESAT/PSI, KU Leuven, Leuven, Belgium
| | - L Vandewinckele I
- KU Leuven - University of Leuven, Department of Oncology, Experimental Radiation Oncology, B-3000 Leuven, Belgium; University Hospitals Leuven, Department of Radiation Oncology, B-3000 Leuven, Belgium
| | - W Crijns
- KU Leuven - University of Leuven, Department of Oncology, Experimental Radiation Oncology, B-3000 Leuven, Belgium; University Hospitals Leuven, Department of Radiation Oncology, B-3000 Leuven, Belgium
| | - F Maes Ir
- Medical Imaging Research Center, University Hospitals Leuven, Leuven, Belgium; Department of Electrical Engineering, ESAT/PSI, KU Leuven, Leuven, Belgium
| | - C G Weltens
- KU Leuven - University of Leuven, Department of Oncology, Experimental Radiation Oncology, B-3000 Leuven, Belgium; University Hospitals Leuven, Department of Radiation Oncology, B-3000 Leuven, Belgium.
| |
Collapse
|
4
|
Corkum MT, Liu W, Palma DA, Bauman GS, Dinniwell RE, Warner A, Mishra MV, Louie AV. Online advertising and marketing claims by providers of proton beam therapy: are they guideline-based? Radiat Oncol 2018; 13:43. [PMID: 29544511 PMCID: PMC5856220 DOI: 10.1186/s13014-018-0988-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Accepted: 03/01/2018] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Cancer patients frequently search the Internet for treatment options, and hospital websites are seen as reliable sources of knowledge. Guidelines support the use of proton radiotherapy in specific disease sites or on clinical trials. This study aims to evaluate direct-to-consumer advertising content and claims made by proton therapy centre (PTC) websites worldwide. METHODS Operational PTC websites in English were identified through the Particle Therapy Co-Operative Group website. Data abstraction of website content was performed independently by two investigators. Eight international guidelines were consulted to determine guideline-based indications for proton radiotherapy. Univariate and multivariate logistic regression models were used to determine the characteristics of PTC websites that indicated proton radiotherapy offered greater disease control or cure rates. RESULTS Forty-eight PTCs with 46 English websites were identified. 60·9% of PTC websites claimed proton therapy provided improved disease control or cure. U.S. websites listed more indications than international websites (15·5 ± 5·4 vs. 10·4 ± 5·8, p = 0·004). The most common disease sites advertised were prostate (87·0%), head and neck (87·0%) and pediatrics (82·6%), all of which were indicated in least one international guideline. Several disease sites advertised were not present in any consensus guidelines, including pancreatobiliary (52·2%), breast (50·0%), and esophageal (43·5%) cancers. Multivariate analysis found increasing number of disease sites and claiming their centre was a local or regional leader in proton radiotherapy was associated with indicating proton radiotherapy offers greater disease control or cure. CONCLUSIONS Information from PTC websites often differs from recommendations found in international consensus guidelines. As online marketing information may have significant influence on patient decision-making, alignment of such information with accepted guidelines and consensus opinion should be adopted by PTC providers.
Collapse
Affiliation(s)
- Mark T. Corkum
- Department of Radiation Oncology, London Health Sciences Centre, 790 Commissioners Road East, London, ON N6A 4L6 Canada
| | - Wei Liu
- Department of Radiation Oncology, London Health Sciences Centre, 790 Commissioners Road East, London, ON N6A 4L6 Canada
| | - David A. Palma
- Department of Radiation Oncology, London Health Sciences Centre, 790 Commissioners Road East, London, ON N6A 4L6 Canada
| | - Glenn S. Bauman
- Department of Radiation Oncology, London Health Sciences Centre, 790 Commissioners Road East, London, ON N6A 4L6 Canada
| | - Robert E. Dinniwell
- Department of Radiation Oncology, London Health Sciences Centre, 790 Commissioners Road East, London, ON N6A 4L6 Canada
| | - Andrew Warner
- Department of Radiation Oncology, London Health Sciences Centre, 790 Commissioners Road East, London, ON N6A 4L6 Canada
| | - Mark V. Mishra
- Departments of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
| | - Alexander V. Louie
- Department of Radiation Oncology, London Health Sciences Centre, 790 Commissioners Road East, London, ON N6A 4L6 Canada
- Department of Epidemiology and Biostatistics, Western University, London, Canada
| |
Collapse
|
5
|
Wang R, Zeidan A, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington S, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. Prostate 2017; 77:437-445. [PMID: 27868212 PMCID: PMC5785924 DOI: 10.1002/pros.23281] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Accepted: 11/04/2016] [Indexed: 01/19/2023]
Abstract
BACKGROUND To understand the impact of radiotherapy on the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) among elderly prostate cancer patients. METHODS We performed a retrospective cohort study of elderly prostate cancer patients diagnosed during 1999-2011 by using the National Cancer Institute's Surveillance, Epidemiology and End Results-Medicare linked database. Competing risk analyses adjusting for patient characteristics were conducted to assess the impact of radiotherapy on the development of subsequent MDS/AML, compared with surgery. RESULTS Of 32,112 prostate cancer patients, 14,672 underwent radiotherapy, and 17,440 received surgery only. The median follow-up was 4.68 years. A total of 157 (0.47%) prostate cancer patients developed subsequent MDS or AML, and the median time to develop MDS/AML was 3.30 (range: 0.16-9.48) years. Compared with prostate cancer patients who received surgery only, patients who underwent radiotherapy had a significantly increased risk of developing MDS/AML (hazard ratio [HR] =1.51, 95% confidence interval [CI]: 1.07-2.13). When radiotherapy was further categorized by modalities (brachytherapy, conventional conformal radiotherapy, and intensity-modulated radiotherapy [IMRT]), increased risk of second MDS/AML was only observed in the IMRT group (HR = 1.66, 95% CI: 1.09-2.54). CONCLUSIONS Our findings suggest that radiotherapy for prostate cancer increases the risk of MDS/AML, and the impact may differ by modality. Additional studies with longer follow-up are needed to further clarify the role of radiotherapy in the development of subsequent myeloid malignancies. A better understanding may help patients, physicians, and other stakeholders make more informed treatment decisions. Prostate 77:437-445, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Cohort Studies
- Follow-Up Studies
- Humans
- Leukemia, Myeloid, Acute/diagnosis
- Leukemia, Myeloid, Acute/epidemiology
- Leukemia, Myeloid, Acute/etiology
- Leukemia, Radiation-Induced/diagnosis
- Leukemia, Radiation-Induced/epidemiology
- Leukemia, Radiation-Induced/etiology
- Male
- Myelodysplastic Syndromes/diagnosis
- Myelodysplastic Syndromes/epidemiology
- Myelodysplastic Syndromes/etiology
- Population Surveillance/methods
- Prostatic Neoplasms/diagnosis
- Prostatic Neoplasms/epidemiology
- Prostatic Neoplasms/radiotherapy
- Radiotherapy, Intensity-Modulated/adverse effects
- Retrospective Studies
- Risk Factors
Collapse
Affiliation(s)
- Rong Wang
- Department of Chronic Disease Epidemiology, Yale School of Public Health
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
| | - Amer Zeidan
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
- Department of Internal Medicine, Yale School of Medicine
| | - James B. Yu
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
- Department of Therapeutic Radiology, Yale School of Medicine
| | - Pamela R. Soulos
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
- Department of Internal Medicine, Yale School of Medicine
| | - Amy J. Davidoff
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
- Department of Health Policy and Management, Yale School of Public Health
| | - Steven D. Gore
- Department of Internal Medicine, Yale School of Medicine
| | - Scott Huntington
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
- Department of Internal Medicine, Yale School of Medicine
| | - Cary P. Gross
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
- Department of Internal Medicine, Yale School of Medicine
| | - Xiaomei Ma
- Department of Chronic Disease Epidemiology, Yale School of Public Health
- Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University
| |
Collapse
|
6
|
Welsh JS, Limmer JP, Howard SP, Diamond D, Harari PM, Tome W. Precautions in the Use of Intensity-Modulated Radiation Therapy. Technol Cancer Res Treat 2016; 4:203-10. [PMID: 15773789 DOI: 10.1177/153303460500400209] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Intensity-modulated radiation therapy (IMRT) represents a significant technological advancement in the ability to deliver highly conformal radiation therapy. Thanks to increased availability, general clinical implementation has become progressively more common. However, there are several precautions worthy of comment regarding the clinical applications of IMRT. In theory, the increased irradiated volume and leakage radiation that occasionally accompanies IMRT could contribute to unanticipated complications and safety concerns. The protracted delivery time of IMRT with the associated increased linac monitor units can result in photoactivation of elements within the linac collimator, thereby inadvertently increasing radiation exposure to patients and staff when high-energy photons are used. The increased volumes of normal tissue exposed to lower doses of radiation through IMRT theoretically could promote carcinogenesis and complications due to the bystander effect, low-dose hyper-radiosensitivity, and diminished repair of double strand DNA breaks at very low doses. Tumor control may be adversely affected by the lower radiation dose-rates of delivery sometimes associated with IMRT as well the occasionally seen low dose “cold shoulder” on the dose-volume histograms. Unusual clinical reactions can appear as a result of the complex, unfamiliar dose-distributions occasionally generated by IMRT treatment planning. Here we discuss some of the precautions worthy of consideration when using IMRT and how these might be addressed in routine practice.
Collapse
Affiliation(s)
- James S Welsh
- Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA.
| | | | | | | | | | | |
Collapse
|
7
|
Muralidhar KR, Soubhagya B, Ahmed S. Intensity modulated radiotherapy versus volumetric modulated arc therapy in breast cancer: A comparative dosimetric analysis. INTERNATIONAL JOURNAL OF CANCER THERAPY AND ONCOLOGY 2015. [DOI: 10.14319/ijcto.32.10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
8
|
Farnia B, Majumder MA, Paulino AC. Ethical analysis as a tool for addressing treatment controversies: radiotherapy timing in children with orbital rhabdomyosarcoma as a case example. J Am Coll Radiol 2014; 12:484-90. [PMID: 25544244 DOI: 10.1016/j.jacr.2014.10.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2014] [Revised: 10/16/2014] [Accepted: 10/20/2014] [Indexed: 11/26/2022]
Abstract
PURPOSE The treatment of orbital rhabdomyosarcoma is a topic of debate between North American and European clinicians, with the utility of radiation therapy as part of initial management in question. Despite differences in philosophy, the dominant North American approach of upfront radiation and the dominant European approach of radiation only in the event of recurrence yield a similar rate of overall survival. We sought to identify the ethical arguments for each approach. METHODS Established moral principles and appeals in contemporary medical ethics were utilized to identify the ethical arguments supporting each treatment approach. The potential for technologic advances to alter the analysis was considered. RESULTS Emphasizing the principle of beneficence, the North American approach seeks to reduce recurrence rates. In contrast, the European approach seeks to avoid radiation-induced sequelae, emphasizing the principle of nonmaleficence. Both approaches are based on well-established ethical principles, evidence, and clinical experience. Thus, both approaches currently appear to have legitimacy and should be included in the informed consent process. However, if treatment-related toxicity is reduced through improvements in radiation delivery, the North American approach could emerge as ethically superior. CONCLUSIONS Ethical analysis can aid in addressing challenges that arise when professional practices and perspectives differ in the management of cancer patients.
Collapse
Affiliation(s)
- Benjamin Farnia
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Mary A Majumder
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas
| | - Arnold C Paulino
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
| |
Collapse
|
9
|
Ozyigit G, Gultekin M. Current role of modern radiotherapy techniques in the management of breast cancer. World J Clin Oncol 2014; 5:425-439. [PMID: 25114857 PMCID: PMC4127613 DOI: 10.5306/wjco.v5.i3.425] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2013] [Revised: 03/07/2014] [Accepted: 05/29/2014] [Indexed: 02/06/2023] Open
Abstract
Breast cancer is the most common type of malignancy in females. Advances in systemic therapies and radiotherapy (RT) provided long survival rates in breast cancer patients. RT has a major role in the management of breast cancer. During the past 15 years several developments took place in the field of imaging and irradiation techniques, intensity modulated RT, hypofractionation and partial-breast irradiation. Currently, improvements in the RT technology allow us a subsequent decrease in the treatment-related complications such as fibrosis and long-term cardiac toxicity while improving the loco-regional control rates and cosmetic results. Thus, it is crucial that modern radiotherapy techniques should be carried out with maximum care and efficiency. Several randomized trials provided evidence for the feasibility of modern radiotherapy techniques in the management of breast cancer. However, the role of modern radiotherapy techniques in the management of breast cancer will continue to be defined by the mature results of randomized trials. Current review will provide an up-to-date evidence based data on the role of modern radiotherapy techniques in the management of breast cancer.
Collapse
|
10
|
Mazeron R, Oberlin O, Dumas I, Kolb F, Goulart J, Rivin E, Haie-Méder C. Brachytherapy in children with rhabdomyosarcomas of the nasolabial fold. Pediatr Blood Cancer 2014; 61:1162-7. [PMID: 24740487 DOI: 10.1002/pbc.24977] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 01/14/2014] [Indexed: 11/06/2022]
Abstract
BACKGROUND Rhabdomyosarcomas (RMS) of the nasolabial fold can be difficult to manage surgically due to functional and cosmetic limitations. Therefore, brachytherapy (BT) has been proposed to improve local control while limiting the volume of irradiation as well as the extent of the surgical excision. MATERIALS AND METHODS Sixteen pediatric cases with RMS of the nasolabial fold treated from 1971 to 2005 were retrospectively reviewed. RESULTS Median follow-up was 4.4 years (1.7-33). Half of the patients were male and their age at diagnosis ranged from 4 months to 13.5 years. Histological subtypes included 10 embryonal and 6 alveolar RMS. Initial treatment consisted of induction multi-agent chemotherapy in all cases. In 12 patients, BT was combined with local excision (4 complete resections, 1 with macroscopic residual disease, and 7 with microscopic disease). Low dose-rate brachytherapy was performed in all cases according to the Paris system, using plastic catheters implanted per-operatively. The doses delivered ranged from 50 to 70 Gy, depending on chemotherapy response, and surgical margin status. 10 patients relapsed: 4 local, 6 regional, and 2 metastatic failures were reported. The median time to relapse was 6.5 months. At the time of analysis eight patients were alive and four had died. Four cases, under palliative care at last check-up, were lost to follow-up. CONCLUSION BT provided an acceptable local control rate, but the poor regional control of these cases may suggest a need for more aggressive management of cervical regional lymph node regions in RMS of the nasolabial fold.
Collapse
Affiliation(s)
- Renaud Mazeron
- Radiation Oncology, Gustave Roussy, Villejuif Cedex, France
| | | | | | | | | | | | | |
Collapse
|
11
|
Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihöfer C, Schüttrumpf L, Ernst A, Niemöller OM, Belka C. Current concepts in clinical radiation oncology. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2014; 53:1-29. [PMID: 24141602 PMCID: PMC3935099 DOI: 10.1007/s00411-013-0497-2] [Citation(s) in RCA: 102] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Accepted: 10/05/2013] [Indexed: 05/04/2023]
Abstract
Based on its potent capacity to induce tumor cell death and to abrogate clonogenic survival, radiotherapy is a key part of multimodal cancer treatment approaches. Numerous clinical trials have documented the clear correlation between improved local control and increased overall survival. However, despite all progress, the efficacy of radiation-based treatment approaches is still limited by different technological, biological, and clinical constraints. In principle, the following major issues can be distinguished: (1) The intrinsic radiation resistance of several tumors is higher than that of the surrounding normal tissue, (2) the true patho-anatomical borders of tumors or areas at risk are not perfectly identifiable, (3) the treatment volume cannot be adjusted properly during a given treatment series, and (4) the individual heterogeneity in terms of tumor and normal tissue responses toward irradiation is immense. At present, research efforts in radiation oncology follow three major tracks, in order to address these limitations: (1) implementation of molecularly targeted agents and 'omics'-based screening and stratification procedures, (2) improvement of treatment planning, imaging, and accuracy of dose application, and (3) clinical implementation of other types of radiation, including protons and heavy ions. Several of these strategies have already revealed promising improvements with regard to clinical outcome. Nevertheless, many open questions remain with individualization of treatment approaches being a key problem. In the present review, the current status of radiation-based cancer treatment with particular focus on novel aspects and developments that will influence the field of radiation oncology in the near future is summarized and discussed.
Collapse
Affiliation(s)
- Michael Orth
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Kirsten Lauber
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Maximilian Niyazi
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Anna A. Friedl
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Minglun Li
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Cornelius Maihöfer
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Lars Schüttrumpf
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Anne Ernst
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Olivier M. Niemöller
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
- Present Address: Clinic for Radiation Oncology, St. Elisabeth Hospital Ravensburg, Ravensburg, Germany
| | - Claus Belka
- Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-University of Munich, Munich, Germany
| |
Collapse
|
12
|
Thariat J, Hannoun-Levi JM, Sun Myint A, Vuong T, Gérard JP. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol 2012. [PMID: 23183635 DOI: 10.1038/nrclinonc.2012.203] [Citation(s) in RCA: 235] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Radiotherapy has been driven by constant technological advances since the discovery of X-rays in 1895. Radiotherapy aims to sculpt the optimal isodose on the tumour volume while sparing normal tissues. The benefits are threefold: patient cure, organ preservation and cost-efficiency. The efficacy and tolerance of radiotherapy were demonstrated by randomized trials in many different types of cancer (including breast, prostate and rectum) with a high level of scientific evidence. Such achievements, of major importance for the quality of life of patients, have been fostered during the past decade by linear accelerators with computer-assisted technology. More recently, these developments were augmented by proton and particle beam radiotherapy, usually combined with surgery and medical treatment in a multidisciplinary and personalized strategy against cancer. This article reviews the timeline of 100 years of radiotherapy with a focus on breakthroughs in the physics of radiotherapy and technology during the past two decades, and the associated clinical benefits.
Collapse
Affiliation(s)
- Juliette Thariat
- Department of Radiation Oncology, Centre Antoine Lacassagne--University Nice Sophia Antipolis, 33 Avenue Valombrose, 06189 Nice, France
| | | | | | | | | |
Collapse
|
13
|
Lopez Guerra JL, Isa N, Kim MM, Bourgier C, Marsiglia H. New perspectives in radiation oncology: Young radiation oncologist point of view and challenges. Rep Pract Oncol Radiother 2012; 17:251-4. [PMID: 24669303 PMCID: PMC3885889 DOI: 10.1016/j.rpor.2012.07.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2011] [Revised: 06/14/2012] [Accepted: 07/10/2012] [Indexed: 10/28/2022] Open
Abstract
AIM To assess the role of the young radiation oncologist in the context of important recent advancements in the field of radiation oncology, and to explore new perspectives and competencies of the young radiation oncologist. BACKGROUND Radiation oncology is a field that has rapidly advanced over the last century. It holds a rich tradition of clinical care and evidence-based practice, and more recently has advanced with revolutionary innovations in technology and computer science, as well as pharmacology and molecular biology. MATERIALS AND METHODS Several young radiation oncologists from different countries evaluated the current status and future directions of radiation oncology. RESULTS For young radiation oncologists, it is important to reflect on the current practice and future directions of the specialty as it relates to the role of the radiation oncologist in the comprehensive management of cancer patients. Radiation oncologists are responsible for the radiation treatment provided to patients and its subsequent impact on patients' quality of life. Young radiation oncologists must proactively master new clinical, biological and technical information, as well as lead radiation oncology teams consisting of physicists, dosimetrists, nurses and technicians. CONCLUSIONS The role of the young radiation oncologist in the field of oncology should be proactive in developing new competencies. Above all, it is important to remember that we are dealing with the family members and loved ones of many individuals during the most difficult part of their lives.
Collapse
Affiliation(s)
- Jose Luis Lopez Guerra
- Department of Radiation Oncology, Instituto Madrileño de Oncologia/Grupo IMO, Madrid, Spain
| | - Nicolas Isa
- Department of Radiation Oncology, Instituto Madrileño de Oncologia/Grupo IMO, Madrid, Spain
- Department of Radiation Oncology, Instituto Nacional del Cancer de Santiago de Chile, Santiago, Chile
| | - Michelle M. Kim
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Celine Bourgier
- Department of Radiation Oncology, Institut de cancérologie Gustave Roussy, Villejuif, Paris, France
| | - Hugo Marsiglia
- Department of Radiation Oncology, Instituto Madrileño de Oncologia/Grupo IMO, Madrid, Spain
- Department of Radiation Oncology, Institut de cancérologie Gustave Roussy, Villejuif, Paris, France
| |
Collapse
|
14
|
Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012; 104:286-93. [DOI: 10.1016/j.radonc.2012.08.013] [Citation(s) in RCA: 446] [Impact Index Per Article: 37.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Revised: 08/24/2012] [Accepted: 08/24/2012] [Indexed: 11/28/2022]
|
15
|
De Neve W, De Gersem W, Madani I. Rational use of intensity-modulated radiation therapy: the importance of clinical outcome. Semin Radiat Oncol 2012; 22:40-9. [PMID: 22177877 DOI: 10.1016/j.semradonc.2011.09.003] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
During the last 2 decades, intensity-modulated radiation therapy (IMRT) became a standard technique despite its drawbacks of volume delineation, planning, robustness of delivery, challenging quality assurance, and cost as compared with non-IMRT. The theoretic advantages of IMRT dose distributions are generally accepted, but the clinical advantages remain debatable because of the lack of clinical assessment of the effort that is required to overshadow the disadvantages. Rational IMRT use requires a positive advantage/drawback balance. Only 5 randomized clinical trials (RCTs), 3 in the breast and 2 in the head and neck, which compare IMRT with non-IMRT (2-dimensional technique in four fifths of the trials), have been published (as of March 2011), and all had toxicity as the primary endpoint. More than 50 clinical trials compared results of IMRT-treated patients with a non-IMRT group, mostly historical controls. RCTs systematically showed a lower toxicity in IMRT-treated patients, and the non-RCTs confirmed these findings. Toxicity reduction, counterbalancing the drawbacks of IMRT, was convincing for breast and head and neck IMRT. For other tumor sites, the arguments favoring IMRT are weaker because of the inability to control bias outside the randomized setting. For anticancer efficacy endpoints, like survival, disease-specific survival, or locoregional control, the balance between advantages and drawbacks is fraught with uncertainties because of the absence of robust clinical data.
Collapse
Affiliation(s)
- Wilfried De Neve
- Department of Radiotherapy, Ghent University Hospital, Ghent, Belgium.
| | | | | |
Collapse
|
16
|
Moskvin V, Cheng CW, Das IJ. Pitfalls of tungsten multileaf collimator in proton beam therapy. Med Phys 2012; 38:6395-406. [PMID: 22149823 DOI: 10.1118/1.3658655] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Particle beam therapy is associated with significant startup and operational cost. Multileaf collimator (MLC) provides an attractive option to improve the efficiency and reduce the treatment cost. A direct transfer of the MLC technology from external beam radiation therapy is intuitively straightforward to proton therapy. However, activation, neutron production, and the associated secondary cancer risk in proton beam should be an important consideration which is evaluated. METHODS Monte Carlo simulation with FLUKA particle transport code was applied in this study for a number of treatment models. The authors have performed a detailed study of the neutron generation, ambient dose equivalent [H∗(10)], and activation of a typical tungsten MLC and compared with those obtained from a brass aperture used in a typical proton therapy system. Brass aperture and tungsten MLC were modeled by absorber blocks in this study, representing worst-case scenario of a fully closed collimator. RESULTS With a tungsten MLC, the secondary neutron dose to the patient is at least 1.5 times higher than that from a brass aperture. The H∗(10) from a tungsten MLC at 10 cm downstream is about 22.3 mSv/Gy delivered to water phantom by noncollimated 200 MeV beam of 20 cm diameter compared to 14 mSv/Gy for the brass aperture. For a 30-fraction treatment course, the activity per unit volume in brass aperture reaches 5.3 × 10⁴ Bq cm(-3) at the end of the last treatment. The activity in brass decreases by a factor of 380 after 24 h, additional 6.2 times after 40 days of cooling, and is reduced to background level after 1 yr. Initial activity in tungsten after 30 days of treating 30 patients per day is about 3.4 times higher than in brass that decreases only by a factor of 2 after 40 days and accumulates to 1.2 × 10⁶ Bq cm(-3) after a full year of operation. The daily utilization of the MLC leads to buildup of activity with time. The overall activity continues to increase due to (179)Ta with a half-life of 1.82 yr and thus require prolonged storage for activity cooling. The H∗(10) near the patient side of the tungsten block is about 100 μSv/h and is 27 times higher at the upstream side of the block. This would lead to an accumulated dose for therapists in a year that may exceed occupational maximum permissible dose (50 mSv/yr). The value of H∗(10) at the upstream surface of the tungsten block is about 220 times higher than that of the brass. CONCLUSIONS MLC is an efficient way for beam shaping and overall cost reduction device in proton therapy. However, based on this study, tungsten seems to be not an optimal material for MLC in proton beam therapy. Usage of tungsten MLC in clinic may create unnecessary risks associated with the secondary neutrons and induced radioactivity for patients and staff depending on the patient load. A careful selection of material for manufacturing of an optimal MLC for proton therapy is thus desired.
Collapse
Affiliation(s)
- Vadim Moskvin
- Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
| | | | | |
Collapse
|
17
|
Riad S, Biau D, Holt GE, Werier J, Turcotte RE, Ferguson PC, Griffin AM, Dickie CI, Chung PW, Catton CN, O'sullivan B, Wunder JS. The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer 2011; 118:2682-92. [DOI: 10.1002/cncr.26543] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2011] [Revised: 08/01/2011] [Accepted: 08/02/2011] [Indexed: 11/12/2022]
|
18
|
West CM, Barnett GC. Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med 2011; 3:52. [PMID: 21861849 PMCID: PMC3238178 DOI: 10.1186/gm268] [Citation(s) in RCA: 121] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Radiotherapy is involved in many curative treatments of cancer; millions of survivors live with the consequences of treatment, and toxicity in a minority limits the radiation doses that can be safely prescribed to the majority. Radiogenomics is the whole genome application of radiogenetics, which studies the influence of genetic variation on radiation response. Work in the area focuses on uncovering the underlying genetic causes of individual variation in sensitivity to radiation, which is important for effective, safe treatment. In this review, we highlight recent advances in radiotherapy and discuss results from four genome-wide studies of radiotoxicity.
Collapse
Affiliation(s)
- Catharine M West
- School of Cancer and Enabling Sciences, The University of Manchester, Manchester Academic Health Science Centre, The Christie, Wilmslow Road, Manchester M20 4BX, UK.
| | | |
Collapse
|
19
|
Munshi A, Pai RH, Phurailatpam R, Budrukkar A, Jalali R, Sarin R, Deshpande D, Shrivastava SK, Dinshaw KA. Do All Patients of Breast Carcinoma Need 3-Dimensional CT-Based Planning? A Dosimetric Study Comparing Different Breast Sizes. Med Dosim 2009; 34:140-4. [DOI: 10.1016/j.meddos.2008.08.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2007] [Revised: 04/30/2008] [Accepted: 08/04/2008] [Indexed: 11/29/2022]
|
20
|
Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, Burnet NG. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9:134-42. [PMID: 19148183 PMCID: PMC2670578 DOI: 10.1038/nrc2587] [Citation(s) in RCA: 508] [Impact Index Per Article: 33.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A key challenge in radiotherapy is to maximize radiation doses to cancer cells while minimizing damage to surrounding healthy tissue. As severe toxicity in a minority of patients limits the doses that can be safely given to the majority, there is interest in developing a test to measure an individual's radiosensitivity before treatment. Variation in sensitivity to radiation is an inherited genetic trait and recent progress in genotyping raises the possibility of genome-wide studies to characterize genetic profiles that predict patient response to radiotherapy.
Collapse
Affiliation(s)
- Gillian C Barnett
- Department of Oncology, University of Cambridge, Oncology Centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.
| | | | | | | | | | | | | |
Collapse
|
21
|
McDonald MW, Godette KD, Butker EK, Davis LW, Johnstone PAS. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis. Int J Radiat Oncol Biol Phys 2008; 72:1031-40. [PMID: 18440727 DOI: 10.1016/j.ijrobp.2008.02.053] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2007] [Revised: 01/31/2008] [Accepted: 02/26/2008] [Indexed: 12/24/2022]
Abstract
PURPOSE To evaluate long-term outcomes of adjuvant breast intensity-modulated radiation therapy (IMRT), with a comparison cohort receiving conventional radiation (cRT) during the same period. METHODS AND MATERIALS Retrospective review identified patients with Stages 0-III breast cancer who underwent irradiation after conservative surgery from January 1999 to December 2003. Computed tomography simulation was used to design standard tangential breast fields with enhanced dynamic wedges for cRT and both enhanced dynamic wedges and dynamic multileaf collimators for IMRT. Patients received 1.8-2-Gy fractions to 44-50.4 Gy to the whole breast, followed by an electron boost of 10-20 Gy. RESULTS A total of 245 breasts were treated in 240 patients: 121 with IMRT and 124 with cRT. Median breast dose was 50 Gy, and median total dose was 60 Gy in both groups. Patient characteristics were well balanced between groups. Median follow-ups were 6.3 years (range, 3.7-104 months) for patients treated with IMRT and 7.5 years (range, 4.9-112 months) for those treated with cRT. Treatment with IMRT decreased acute skin toxicity of Radiation Therapy Oncology Group Grade 2 or 3 compared with cRT (39% vs. 52%; p = 0.047). For patients with Stages I-III (n = 199), 7-year Kaplan-Meier freedom from ipsilateral breast tumor recurrence (IBTR) rates were 95% for IMRT and 90% for cRT (p = 0.36). For patients with Stage 0 (ductal carcinoma in situ, n = 46), 7-year freedom from IBTR rates were 92% for IMRT and 81% for cRT (p = 0.29). Comparing IMRT with cRT, there were no statistically significant differences in overall survival, disease-specific survival, or freedom from IBTR, contralateral breast tumor recurrence, distant metastasis, late toxicity, or second malignancies. CONCLUSIONS Patients treated with breast IMRT had decreased acute skin toxicity, and long-term follow-up shows excellent local control similar to a contemporaneous cohort treated with cRT.
Collapse
Affiliation(s)
- Mark W McDonald
- Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA.
| | | | | | | | | |
Collapse
|
22
|
Marks LB, Ma J. Challenges in the clinical application of advanced technologies to reduce radiation-associated normal tissue injury. Int J Radiat Oncol Biol Phys 2007; 69:4-12. [PMID: 17707263 DOI: 10.1016/j.ijrobp.2007.05.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2007] [Revised: 05/07/2007] [Accepted: 05/07/2007] [Indexed: 11/21/2022]
Affiliation(s)
- Lawrence B Marks
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
| | | |
Collapse
|
23
|
Nadeau S, Bouchard M, Germain I, Raymond PE, Beaulieu F, Beaulieu L, Roy R, Gingras L. Postoperative Irradiation of Gynecologic Malignancies: Improving Treatment Delivery Using Aperture-Based Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68:601-11. [PMID: 17418966 DOI: 10.1016/j.ijrobp.2007.01.046] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2006] [Revised: 01/10/2007] [Accepted: 01/11/2007] [Indexed: 11/17/2022]
Abstract
PURPOSE To evaluate dosimetric and treatment delivery advantages of aperture-based intensity-modulated radiotherapy (AB-IMRT) for the treatment of patients receiving whole pelvic radiotherapy for gynecologic malignancies. METHODS AND MATERIALS Nineteen patients undergoing pelvic radiotherapy after resection of endometrial cancers were selected. A 45-Gy dose was prescribed to the target volume delineated on a planning CT scan. An in-house inverse planning system, Ballista, was used to develop a treatment plan using aperture-based multileaf collimator segments. This approach was compared with conventional four-field, enlarged four-field, and static beamlet-based IMRT (BB-IMRT) techniques in terms of target coverage, dose-volume histogram statistics for surrounding normal tissues, and numbers of segments and monitor units (MU). RESULTS Three quarters (76.4%) of the planning target volume received the prescription dose with conventional four-field plans. With adequate target coverage, the Ballista plans significantly reduced the volume of bowel and bladder irradiated at the prescribed dose (p < 0.001), whereas the two approaches provided equivalent results for the rectum (p = 0.5). On the other hand, AB-IMRT and BB-IMRT plans showed only small differences in dose-volume histogram statistics of unknown clinical impact, whereas Ballista plan delivery required on average 73% and 59% fewer segments and MU, respectively. CONCLUSION With respect to conventional techniques, AB-IMRT for the treatment of gynecologic malignancies provides dosimetric advantages similar to those with BB-IMRT but with clear treatment delivery improvements.
Collapse
Affiliation(s)
- Sylvain Nadeau
- Département de physique, de génie physique et d'optique, Université Laval, Québec, QC, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Smith RP, Heron DE, Huq MS, Yue NJ. Modern radiation treatment planning and delivery--from Röntgen to real time. Hematol Oncol Clin North Am 2006; 20:45-62. [PMID: 16580556 DOI: 10.1016/j.hoc.2006.01.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The field of radiation oncology has advanced exponentially since the discovery of X-rays just over 100 years ago. With the advent of three-dimensional treatment planning, the therapeutic index was increased by dose escalation and more accurate shielding of normal tissues. Now, even greater advances are under way with IMRT, image-guided radiation therapy, delineation and control of organ motion, and real-time imaging. Similarly, the use of particle therapies such as protons has the potential to effect even more accurate dose distributions. Clinical studies investigating these modalities will likely further increase the efficacy of radiation in years to come.
Collapse
Affiliation(s)
- Ryan P Smith
- Department of Radiation Oncology, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, Suite 545, Pittsburgh, PA 15232, USA
| | | | | | | |
Collapse
|
25
|
Barnes MM. Why aren't community radiation oncologists adhering to evidence-based guidelines? ACTA ACUST UNITED AC 2006. [DOI: 10.1016/s1548-5315(11)70911-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Puri DR, Wexler LH, Meyers PA, La Quaglia MP, Healey JH, Wolden SL. The challenging role of radiation therapy for very young children with rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2006; 65:1177-84. [PMID: 16682130 DOI: 10.1016/j.ijrobp.2006.02.014] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2005] [Revised: 02/03/2006] [Accepted: 02/06/2006] [Indexed: 11/16/2022]
Abstract
PURPOSE To evaluate local control and toxicity for very young children treated with multimodality therapy for rhabdomyosarcoma (RMS). METHODS AND MATERIALS From 1990 to 2004, 20 patients<or=36 months at diagnosis were treated at our institution. Nineteen underwent chemotherapy (CMT), surgery and/or intraoperative high-dose-rate brachytherapy (IOHDR), and external-beam radiation (EBRT). Median age was 17 months. Sites included extremity (7), trunk (5), parameningeal (4), orbit (1), head/neck (1), bladder/prostate (1). Histologies consisted of 10 embryonal (53%) and 9 alveolar/undifferentiated (47%). Ten had delayed gross total resection (GTR) at median time of 17 weeks after the start of CMT, and 8 of these underwent IOHDR. Median interval between start of CMT and EBRT was 18 weeks. Median EBRT dose was 36 Gy. EBRT technique was either intensity-modulated (11), three-dimensional (3), or two-dimensional (5). Functional outcome was assessed for patients alive>or=1 year after diagnosis (15) in terms of mild, moderate, or severe deficits. RESULTS Median follow-up was 33 months for survivors and 23 months for all patients. Two-year actuarial local control, event-free survival, disease-specific survival, and overall survival were 84%, 52%, 74%, and 62%, respectively. All patients who began EBRT<or=18 weeks after the start of CMT had their disease controlled locally. Five have mild deficits and 10 have no deficits. CONCLUSIONS A reduced dose of 36-Gy EBRT after delayed GTR may maximize local control while minimizing long-term sequelae for very young children with RMS, but unresectable tumors (e.g., parameningeal) require higher doses. Normal-tissue-sparing techniques such as intensity-modulated radiation therapy and IOHDR are encouraged. Local control may be maximized when EBRT begins <or=18 weeks after initiation of CMT, but further study is warranted. Longer follow-up is required to determine the full extent of late effects.
Collapse
Affiliation(s)
- Dev R Puri
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | |
Collapse
|
27
|
Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. Int J Radiat Oncol Biol Phys 2006; 64:892-7. [PMID: 16458777 DOI: 10.1016/j.ijrobp.2005.05.067] [Citation(s) in RCA: 106] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2005] [Revised: 04/15/2005] [Accepted: 05/06/2005] [Indexed: 01/06/2023]
Abstract
PURPOSE To report preliminary clinical and dosimetric data from intensity-modulated radiotherapy (IMRT) for malignant gliomas. METHODS AND MATERIALS Fifty-eight consecutive high-grade gliomas were treated between January 2001 and December 2003 with dynamic multileaf collimator IMRT, planned with the inverse approach. A dose of 59.4-60 Gy at 1.8-2.0 Gy per fraction was delivered. A total of three to five noncoplanar beams were used to cover at least 95% of the target volume with the prescription isodose line. Glioblastoma accounted for 70% of the cases, and anaplastic oligodendroglioma histology (pure or mixed) was seen in 15% of the cases. Surgery consisted of biopsy only in 26% of the patients, and 80% received adjuvant chemotherapy. RESULTS With a median follow-up of 24 months, 85% of the patients have relapsed. The median progression-free survival time for anaplastic astrocytoma and glioblastoma histology was 5.6 and 2.5 months, respectively. The overall survival time for anaplastic glioma and glioblastoma was 36 and 9 months, respectively. Ninety-six percent of the recurrences were local. No Grade IV/V late neurologic toxicities were noted. A comparative dosimetric analysis revealed that regardless of tumor location, IMRT did not significantly improve target coverage compared with three-dimensional planning. However, IMRT resulted in a decreased maximum dose to the spinal cord, optic nerves, and eye by 16%, 7%, and 15%, respectively, owing to its improved dose conformality. The mean brainstem dose also decreased by 7%. Intensity-modulated radiotherapy delivered with a limited number of beams did not result in an increased dose to the normal brain. CONCLUSIONS It is unlikely that IMRT will improve local control in high-grade gliomas without further dose escalation compared with conventional radiotherapy. However, it might result in decreased late toxicities associated with radiotherapy.
Collapse
Affiliation(s)
- Ashwatha Narayana
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| | | | | | | | | | | | | |
Collapse
|
28
|
Mu X, Björk-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, Johansson L, Karlsson M, Zackrisson DB. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol 2006; 44:554-62. [PMID: 16165914 DOI: 10.1080/02841860500218819] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The aim of this treatment planning comparison study was to explore different spinal irradiation techniques with respect to the risk of late side-effects, particularly radiation-induced cancer. The radiotherapy techniques compared were conventional photon therapy, intensity modulated x-ray therapy (IMXT), conventional electron therapy, intensity/energy modulated electron therapy (IMET) and proton therapy (IMPT).CT images for radiotherapy use from five children, median age 8 and diagnosed with medulloblastoma, were selected for this study. Target volumes and organs at risk were defined in 3-D. Treatment plans using conventional photon therapy, IMXT, conventional electron therapy, IMET and IMPT were set up. The probability of normal tissue complication (NTCP) and the risk of cancer induction were calculated using models with parameters-sets taken from published data for the general population; dose data were taken from dose volume histograms (DVH). Similar dose distributions in the targets were achieved with all techniques but the absorbed doses in the organs-at-risk varied significantly between the different techniques. The NTCP models based on available data predicted very low probabilities for side-effects in all cases. However, the effective mean doses outside the target volumes, and thus the predicted risk of cancer induction, varied significantly between the techniques. The highest lifetime risk of secondary cancers was estimated for IMXT (30%). The lowest risk was found with IMPT (4%). The risks associated with conventional photon therapy, electron therapy and IMET were 20%, 21% and 15%, respectively. This model study shows that spinal irradiation of young children with photon and electron techniques results in a substantial risk of radiation-induced secondary cancers. Multiple beam IMXT seems to be associated with a particularly high risk of secondary cancer induction. To minimise this risk, IMPT should be the treatment of choice. If proton therapy is not available, advanced electron therapy may provide a better alternative.
Collapse
Affiliation(s)
- Xiangkui Mu
- Department of Radiation Sciences, Oncology, Umeå University, SE-901 87, Umeå, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
There is increasing concern regarding radiation-related second-cancer risks in long-term radiotherapy survivors and a corresponding need to be able to predict cancer risks at high radiation doses. Although cancer risks at moderately low radiation doses are reasonably understood from atomic bomb survivor studies, there is much more uncertainty at the high doses used in radiotherapy. It has generally been assumed that cancer induction decreases rapidly at high doses due to cell killing. However, recent studies of radiation-induced second cancers in the lung and breast, covering a very wide range of doses, contradict this assumption. A likely resolution of this disagreement comes from considering cellular repopulation during and after radiation exposure. Such repopulation tends to counteract cell killing and accounts for the large discrepancies between the current standard model for cancer induction at high doses and recent second-cancer data. We describe and apply a biologically based minimally parameterized model of dose-dependent cancer risks, incorporating carcinogenic effects, cell killing, and, additionally, proliferation/repopulation effects. Including stem-cell repopulation leads to risk estimates consistent with high-dose second-cancer data. A simplified version of the model provides a practical and parameter-free approach to predicting high-dose cancer risks, based only on data for atomic bomb survivors (who were exposed to lower total doses) and the demographic variables of the population of interest. Incorporating repopulation effects provides both a mechanistic understanding of cancer risks at high doses and a practical methodology for predicting cancer risks in organs exposed to high radiation doses, such as during radiotherapy.
Collapse
Affiliation(s)
- Rainer K Sachs
- Department of Mathematics, University of California, Berkeley, CA 94720, USA
| | | |
Collapse
|
30
|
Braaksma M, van Agthoven M, Nijdam W, Uyl-de Groot C, Levendag P. Costs of treatment intensification for head and neck cancer: Concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer 2005; 41:2102-11. [PMID: 16140526 DOI: 10.1016/j.ejca.2005.05.012] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2005] [Revised: 05/06/2005] [Accepted: 05/13/2005] [Indexed: 11/26/2022]
Abstract
This study presents an overview of costs of a chemoradiation protocol in head and neck cancer patients and an analysis of whether prevention of acute toxicity with amifostine results in a reduction to costs. Fifty-four patients treated with weekly paclitaxel concomitant with radiation were randomised for treatment with subcutaneously administered amifostine (500 mg) and analysed with respect to costs of treatment. Total costs for work-up, treatment and toxicity were calculated per treatment arm. No significant differences were found between treatment arms in preliminary results regarding response (98%), toxicity and 2-year survival (77%). Average costs for toxicity were Euro 3.789, largely influenced by hospital admissions (Euro 3.013). Total costs for amifostine administration amounted to Euro 6.495 per patient. The average total costs of treatment were Euro 19.647 versus Euro 13.592 with or without amifostine, respectively. The applied (subcutaneous) dose of amifostine appeared to be insufficient for radioprotection and reduction of related costs in the concomitant chemoradiation scheme, whereas total costs increased remarkably. Although it would be accompanied by a further cost raise, applying a higher amifostine dose might reduce (mucosal) toxicity and therefore in the long run lower related costs for hospital admission and tube feeding.
Collapse
Affiliation(s)
- Marijel Braaksma
- Department of Radiation Oncology, Erasmus Medical Center-Daniel den Hoed, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
| | | | | | | | | |
Collapse
|
31
|
Al-Yahya K, Schwartz M, Shenouda G, Verhaegen F, Freeman C, Seuntjens J. Energy modulated electron therapy using a few leaf electron collimator in combination with IMRT and 3D-CRT: Monte Carlo-based planning and dosimetric evaluation. Med Phys 2005; 32:2976-86. [PMID: 16266112 DOI: 10.1118/1.2011089] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Energy modulated electron therapy (EMET) based on Monte Carlo dose calculation is a promising technique that enhances the treatment planning and delivery of superficially located tumors. This study investigated the application of EMET using a novel few-leaf electron collimator (FLEC) in head and neck and breast sites in comparison with three-dimensional conventional radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) techniques. Treatment planning was performed for two parotid cases and one breast case. Four plans were compared for each case: 3D-CRT, IMRT, 3D-CRT in conjunction with EMET (EMET-CRT), and IMRT in conjunction with EMET (EMET-IMRT), all of which were performed and calculated with Monte Carlo techniques. For all patients, dose volume histograms (DVHs) were obtained for all organs of interest and the DVHs were used as a means of comparing the plans. Homogeneity and conformity of dose distributions were calculated, as well as a sparing index that compares the effect of the low isodose lines. In addition, the whole-body dose equivalent (WBDE) was estimated for each plan. Adding EMET delivered with the FLEC to 3D-CRT improves sparing of normal tissues. For the two head and neck cases, the mean dose to the contralateral parotid and brain stem was reduced relative to IMRT by 43% and 84%, and by 57% and 71%, respectively. Improved normal tissue sparing was quantified as an increase in sparing index of 47% and 30% for the head and neck and the breast cases, respectively. Adding EMET to either 3D-CRT or IMRT results in preservation of target conformity and dose homogeneity. When adding EMET to the treatment plan, the WBDE was reduced by between 6% and 19% for 3D-CRT and by between 21% and 33% for IMRT, while WBDE for EMET-CRT was reduced by up to 72% when compared with IMRT. FLEC offers a practical means of delivering modulated electron therapy. Although adding EMET delivered using the FLEC results in perturbation of target conformity when compared to IMRT, it significantly improves normal tissue sparing while offering enhanced target conformity to the 3D-CRT planning. The addition of EMET systematically leads to a reduction in WBDE especially when compared with IMRT.
Collapse
Affiliation(s)
- Khalid Al-Yahya
- Medical Physics Unit, McGill University, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.
| | | | | | | | | | | |
Collapse
|
32
|
Cady J. Navigating external beam radiation therapy for head and neck cancer. Clin J Oncol Nurs 2005; 9:362-6. [PMID: 15973848 DOI: 10.1188/05.cjon.362-366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Jormain Cady
- Virginia Mason Medical Center, Seattle, WA, USA.
| |
Collapse
|
33
|
Craig T, Wong E, Bauman G, Battista J, Van Dyk J. Impact of geometric uncertainties on evaluation of treatment techniques for prostate cancer. Int J Radiat Oncol Biol Phys 2005; 62:426-36. [PMID: 15890584 DOI: 10.1016/j.ijrobp.2004.09.016] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2004] [Revised: 09/14/2004] [Accepted: 09/17/2004] [Indexed: 11/16/2022]
Abstract
PURPOSE To assess the impact of patient repositioning and internal organ motion on prostate treatment plans using three-dimensional conformal and intensity-modulated radiotherapy. METHODS AND MATERIALS Four-field, six-field, and simplified intensity-modulated arc therapy plans were generated for 5 prostate cancer patients. The planning target volume was created by adding a 1-cm margin to the clinical target volume. A convolution model was used to estimate the effect of random geometric uncertainties during treatment. Dose statistics, tumor control probabilities, and normal tissue complication probabilities were compared with and without the presence of uncertainty. The impact of systematic uncertainties was also investigated. RESULTS Compared with the planned treatments, the delivered dose distribution with random geometric uncertainties displayed an increase in the apparent minimal dose to the prostate and seminal vesicles and a decrease in the rectal volume receiving a high dose. This increased the tumor control probabilities and decreased the normal tissue complication probabilities. Changes were seen in the percentage of prostate volume receiving 100% and 95% of the prescribed dose, and the minimal dose and tumor control probabilities for the target volume. In addition, the volume receiving at least 65 Gy, the minimal dose, and normal tissue complication probabilities changed considerably for the rectum. The simplified intensity-modulated arc therapy technique was the most sensitive to systematic errors, especially in the anterior-posterior and superior-inferior directions. CONCLUSION Geometric uncertainties should be considered when evaluating treatment plans. Contrary to the widely held belief, increased conformation of the dose distribution is not always associated with increased sensitivity to random geometric uncertainties if a sufficient planning target volume margin is used. Systematic errors may have a variable effect, depending on the treatment technique used.
Collapse
Affiliation(s)
- Tim Craig
- Radiation Treatment Program, London Regional Cancer Program, London Health Sciences Centre, London, ON, Canada
| | | | | | | | | |
Collapse
|
34
|
Wolden SL, Wexler LH, Kraus DH, Laquaglia MP, Lis E, Meyers PA. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2005; 61:1432-8. [PMID: 15817347 DOI: 10.1016/j.ijrobp.2004.08.005] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2004] [Revised: 08/03/2004] [Accepted: 08/09/2004] [Indexed: 11/29/2022]
Abstract
PURPOSE To determine the preliminary results of intensity-modulated radiotherapy (IMRT) for head-and-neck rhabdomyosarcoma. METHODS AND MATERIALS Twenty-eight patients underwent IMRT as a part of multimodality therapy. Twenty-one tumors were parameningeal, three were orbital, and four were in other sites. The median age was 8 years (range, 1-29 years). Most (89%) had Group III disease. Intracranial extension was present in 71% of parameningeal tumors. A 1.5-cm margin was used, and the median dose was 50.4 Gy (range, 30-55.8 Gy). RESULTS The actuarial 3-year survival rate for patients with parameningeal tumors was 65%. The 3-year actuarial freedom from failure rate was 95% locally, 90% in regional nodes, 88% in the central nervous system, and 80% at distant sites. No failures occurred among patients with orbit tumors; a single central nervous system failure occurred in 1 patient with a lip/cheek tumor. Disease-free survival was significantly worse for patients with alveolar histologic features (p = 0.01). Acute radiation toxicity was similar to that reported by the Intergroup Rhabdomyosarcoma Study Group. Late radiation toxicity was recorded and was mild. CONCLUSION IMRT with image fusion results in outstanding local control despite the use of a reduced margin. However, survival among patients with alveolar histologic findings or intracranial extension remains unacceptably low.
Collapse
Affiliation(s)
- Suzanne L Wolden
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
| | | | | | | | | | | |
Collapse
|
35
|
Mu X, Olofsson L, Karlsson M, Sjögren R, Zackrisson B. Can photon IMRT be improved by combination with mixed electron and photon techniques? Acta Oncol 2005; 43:727-35. [PMID: 15764217 DOI: 10.1080/02841860410002761] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Conformal radiotherapy or intensity modulated radiotherapy (IMRT) commonly leads to a large integral dose in the patient. Electrons would reduce the integral dose but are not suitable for treating deep-seated tumours, owing to their limited penetration. By combining electron and photon beams, the dose distributions may be improved. In this study, the possibility is explored of using a mixture of electron and photon beams for a deep-seated target volume in the head and neck region. Treatment plans were made for five simulated head and neck cancer cases. Mixed electron and photon beam plans (MB) were constructed using a manual iterative procedure. Photon IMRT plans were optimized automatically. Both electron and photon beams were collimated by a computer controlled multi-leaf collimator (MLC). Both methods were able to produce clinically acceptable plans. Criteria for the target dose were met similarly by both as were the criteria for critical organs. The integral dose outside the planning target volume (PTV) showed a tendency to be lower with MB plans compared with photon IMRT plans. A mixed electron and photon technique has the potential to treat deep-seated tumours. It is reasonable to expect that if computerized optimization tools were coupled with the mixed electron and photon beam technique, treatment goals would be more readily achieved than if using solely pure photon IMRT.
Collapse
Affiliation(s)
- Xiangkui Mu
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | | | | | | | | |
Collapse
|
36
|
Saarilahti K, Kouri M, Collan J, Hämäläinen T, Atula T, Joensuu H, Tenhunen M. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 2004; 74:251-8. [PMID: 15763305 DOI: 10.1016/j.radonc.2004.11.004] [Citation(s) in RCA: 114] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2004] [Revised: 10/14/2004] [Accepted: 11/03/2004] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE To investigate the salivary gland function following intensity modulated radiotherapy (IMRT) for head and neck cancer. PATIENTS AND METHODS Seventeen patients with oropharyngeal (n=11) or nasopharyngeal (n=6) carcinoma located adjacent to the major salivary glands were treated with IMRT with an emphasis to spare the salivary glands from high-dose irradiation and to reduce the risk of postirradiation xerostomy. Three patients had stage 2, 4 stage III, and 10 stage IVA cancer. The total basal and stimulated saliva flow rates were measured before the treatment, and 6 and 12 months after radiotherapy. RESULTS The median basal saliva flow rate measured before radiation treatment was 0.13 mL/min, and at 6 and 12 months after the completion of IMRT 0.04 mL/min and 0.07 mL/min, respectively. The corresponding median stimulated saliva flow rates were 0.49 mL/min, 0.33 mL/min, and 0.45 mL, respectively. The D50 for an impaired stimulated parotid gland saliva flow rate was 25.5 Gy. Only two (12%) patients developed grade 3 and none grade 4 xerostomia during a median follow-up of 24 months (range, 12-40 months). No patients had locoregional cancer recurrence following IMRT. CONCLUSIONS The results suggest that much of the salivary gland function can be maintained with IMRT without jeopardizing the local control rate in the treatment of locally advanced oropharynx or nasopharynx carcinoma.
Collapse
Affiliation(s)
- Kauko Saarilahti
- Department of Oncology, Helsinki University Central Hospital, POB-180, FIN-00029 HUS Helsinki, Finland
| | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
There have been considerable technical improvements in radiation therapy for the past two decades. In children affected with cancer, these have been likely overshadowed by concommittant major chemotherapy-based advances, and at least in part ignored and misused. This article outlines principles, technological requirements, and clinical applications of innovations that aim at improving ballistical selectivity (such as conformal, intensity modulation, stereotactic photons, charged particles, and intraoperative therapies), as well as at influencing tumors and normal tissues sensitivity to radiations (such as high LET particles, and altered fractionations).
Collapse
Affiliation(s)
- Jean-Louis Habrand
- Pediatric Unit, Department of Radiation Oncology, Institut Gustave-Roussy, Villejuif, France.
| | | | | |
Collapse
|
38
|
McNair HA, Francis G, Balyckyi J. Clinical implementation of dynamic intensity-modulated radiotherapy: radiographers' perspectives. Br J Radiol 2004; 77:493-8. [PMID: 15151970 DOI: 10.1259/bjr/82394256] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The ability of intensity-modulated radiotherapy (IMRT) to sculpt the dose distribution closely around the tumour volume has the potential to have a major impact on radiotherapy clinical practice. However, dynamic IMRT treatment delivery differs from that of conventional treatment because of the constantly moving multileaf collimators (MLCs) and higher monitor units (MUs) required. The implementation of new technology can be affected by the users response. Radiographers' attitudes regarding technology and their perceptions of the clinical implementation of IMRT were explored using a qualitative study based on semi-structured interviews. 16 radiographers were interviewed and data was analysed using a framework analysis to identify themes and categories. The majority of radiographers (12/16) demonstrated positive attitudes regarding technology. The introduction of IMRT was seen to be stimulating and motivating. Negative aspects were associated with increased stress from learning new skills and the additional pressure of the increased workload. Although there were contradictory views regarding the effect of the increased use of technology on the patient-radiographer relationship, technological skills and patient care were not found to be mutually exclusive. Radiographers' perceptions regarding the clinical implementation of IMRT appeared to be influenced by their mainly positive attitudes regarding technology. With the current problems of recruitment and retention of radiographers, full exploitation of modern technology could be used to improve job satisfaction. However, careful integration is required to balance training needs with service demands.
Collapse
Affiliation(s)
- H A McNair
- Radiotherapy Department, Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK
| | | | | |
Collapse
|
39
|
Capp A, Metcalfe P. IMRT: is it Nirvana? PROGRESS IN PALLIATIVE CARE 2004. [DOI: 10.1179/096992604225004561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
40
|
Brezovich IA. IMRT may be used to excess because of its higher reimbursement from medicare. Med Phys 2003; 31:2-3. [PMID: 14761014 DOI: 10.1118/1.1630968] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Affiliation(s)
- Ivan A Brezovich
- University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama 35294, USA.
| |
Collapse
|
41
|
Arriagada R, Le Péchoux C, Pignon JP. Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. Lung Cancer 2003; 42 Suppl 1:S57-64. [PMID: 14611916 DOI: 10.1016/s0169-5002(03)00309-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Even if postoperative thoracic radiotherapy has been widely used as adjuvant treatment, the oncological community has poorly evaluated this treatment after complete surgical resection in lung cancer. The number of patients included in randomised trials has been less than 3000. The analysis of these trials showed rather a deleterious effect in terms of overall survival, suggesting a lethal late treatment-related toxicity in early stage I or II disease. In N2 disease, these effects have not been demonstrated but information is lacking to consider this treatment on an evidence-based medicine policy. We discuss here the available worldwide information on this subject. There is an urgent need for new trials in this topic.
Collapse
Affiliation(s)
- Rodrigo Arriagada
- Instituto de Radiomedicina (IRAM), Américo Vespucio Norte 1314, Vitacura, Santiago, Chile.
| | | | | |
Collapse
|
42
|
Schellhammer PF. Editorial: Improving Outcomes for Primary and Salvage Therapy of Localized Prostate Cancer. J Urol 2003; 170:1841-2. [PMID: 14532788 DOI: 10.1097/01.ju.0000092223.19256.6b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
43
|
|
44
|
Childress NL, Rosen II. The design and testing of novel clinical parameters for dose comparison. Int J Radiat Oncol Biol Phys 2003; 56:1464-79. [PMID: 12873692 DOI: 10.1016/s0360-3016(03)00430-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE New multidimensional dose comparison parameters, normalized agreement test (NAT) values and the NAT index, are introduced and compared with an ideal dose comparison parameter. In this article, we analyze a clinically based two-dimensional (2D) quantitative dose comparison case using a wide range of new and old comparison tools. In doing so, we address the benefits and limitations of many common dose comparison tools. METHODS AND MATERIALS An in-house software program was developed using the MATLAB 6.5 programming language. Using this software, several 2D quantitative dose comparison parameters were calculated for the computed and measured dose distributions in an intensity-modulated radiotherapy (IMRT) prostate cancer treatment. The experiences gained in the design and testing of this software program form the basis of the dose comparison tool analysis. RESULTS Each dose comparison tool has unique strengths and weaknesses. The underlying assumptions of the NAT values and NAT index lead to acceptable generalized behavior, but are not always valid. CONCLUSION A thorough 2D quantitative dose comparison analysis can only be accomplished through the use of many dose comparison tools. The introduction of the NAT index allows a 2D dose comparison to be reduced to a single value, and is thus ideal for setting clinical acceptance criteria for IMRT verifications.
Collapse
Affiliation(s)
- Nathan L Childress
- Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | |
Collapse
|
45
|
Coleman CN. Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!). Radiology 2003; 228:29-35. [PMID: 12832573 DOI: 10.1148/radiol.2281021567] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Among the areas defined by the National Cancer Institute as "Extraordinary Opportunities for Research Investment" that are highly relevant to the technology-oriented disciplines within the broad field of radiology are cancer imaging, defining the signatures (ie, underlying molecular features) of cancer cells, and molecular targets of prevention and treatment. In molecular target credentialing, a specific molecular target is imaged, the molecular signature is defined, a treatment is given, and the effect of the intervention on the image findings and the signature is then evaluated. Such an approach is used to validate the proposed target as a legitimate one for cancer therapy or prevention and to provide the opportunity to ultimately individualize therapy on the basis of both the initial characteristics of the tumor and the tumor's response to an intervention. Therapeutic radiation is focused biology (ie, radiation produces molecular events in the irradiated tissue). Radiation can (a) kill cancer cells by itself, (b) be combined with cytotoxic or cytostatic drugs, and (c) serve to initiate radiation-inducible molecular targets that are amenable to treatment with drugs and/or biologic therapies. Focused biology can be anatomically confined with various types of external beams and with brachytherapy, and it can be used systemically with targeted radioisotopes. These new paradigms link diagnostic imaging, radiation therapy, and nuclear medicine in unique ways by way of basic biology. It is timely to develop new collaborative research, training, and education agendas by building on one another's expertise and adopting new fields of microtechnology, nanotechnology, and mathematical analysis and optimization.
Collapse
Affiliation(s)
- C Norman Coleman
- National Cancer Institute, Radiation Oncology Branch, Bldg 10, B3-B69, National Institutes of Health, Bethesda, MD 20892-1002, USA.
| |
Collapse
|
46
|
|
47
|
Abstract
One reason for the high death rate of lung cancer is that tumours are not usually detected until the disease is at a late stage, at which point the cancer is non-curable. Spiral computerized tomography is a highly sensitive imaging method that could be used to screen high-risk populations, such as current or former smokers, for early-stage tumours. Trials to validate this tool are just underway, but beyond the imaging tools, population-based care of pre-metastatic lung cancer requires considerable evolution in clinical management approaches. More sensitive imaging tools might also provide a window into earlier biology, enabling the molecular dynamics of lung cancer progression to be elucidated.
Collapse
Affiliation(s)
- James L Mulshine
- Intervention Section, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes for Health, Bethesda, Maryland 20892-1906, USA.
| |
Collapse
|